Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Morrisette, Taylor; Molina, Kyle C; Silva, Beatriz Da; Mueller, Scott W.; Damioli, Laura; Kršák, Martin; Miller, Matthew A.; Fish, Douglas N.

doi:10.1093/ofid/ofac028

Cited by 10 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are similar to that of Morisette et al, who retrospectively looked at safety of prolonged tedizolid in 37 subjects who took tedizolid for a mean of 188 days ( 18 ), compared to our median of 96 days. In their study, they similarly found no new clinically significant hematologic cytopenias or neuropathies.…”

Section: Discussionsupporting

confidence: 90%

“…In terms of efficacy, we found a treatment failure rate of 11%, similar to the rates of 6%–24% reported by others ( 18 – 20 , 23 ). How these treatment failure rates compare to that of other antimicrobial regimens, intravenous or oral, is unclear.…”

Section: Discussionsupporting

confidence: 90%

“…Second, we used systematic measures of surveying for laboratory abnormalities as well as new neurologic symptoms. Finally, our subjects had a diversity of BJI types, including native bone infections that were not studied ( 19 , 20 ) or formed only a minority of patients ( 18 , 23 ) in the other investigations of tedizolid therapy.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Miller,

Flores,

Launer

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens. In animal studies and short-term human use, tedizolid lacks the hematologic and neurologic toxicity of the other available oxazolidinone, linezolid. However, there are limited prospective safety data. We conducted an open-label, non-comparative trial of oral tedizolid for BJI treatment. Primary outcomes were safety and cure rate. Eligible patients had a BJI caused by documented or suspected Gram-positive pathogen, required 4–12 weeks of therapy, and did not have myelosuppression or peripheral/optic neuropathy. Subjects underwent weekly evaluation for cytopenias and neuropathy. We enrolled 44 subjects; five were lost to follow-up. Two subjects did not complete planned treatment because of rash ( n = 1) and urgent surgery ( n = 1). Of 37 patients with evaluable outcomes, 17 (46%) had hardware-associated infection, 13 (35%) had osteomyelitis, 5 (14%) had prosthetic joint infection, and 2 (5%) had other BJIs. Median (mean, range) treatment duration was 12 (10.1, 4–12) weeks. There were no cases of cytopenias or peripheral or optic neuropathy. Treatment cure occurred in 13 (35%); 19 (51%) required antibiotic continuation after 12 weeks of tedizolid related to retained hardware at the BJI site, and failure occurred in four (11%), two unlikely, one possibly, and one probably due to tedizolid. We found that oral tedizolid was well tolerated for prolonged BJI treatment without significant toxicity. Clinical failure rate was similar to that of other published BJI investigations. (This study has been registered at Clinicaltrials.gov under identifier NCT03009045.) IMPORTANCE Bone and joint infections are common infections with limited effective and safe oral options for Gram-positive infections. The largest prospective clinical trial of tedizolid therapy for bone and joint infections enrolled 44 patients and tested each in person weekly with detailed safety monitoring including tests for leukopenia, anemia, thrombocytopenia, peripheral neuropathy, and optic neuropathy for up to 12 weeks. Findings demonstrated tedizolid was generally well tolerated and there were no incident cases of cytopenias or neuropathy. Cure rates were similar to that in other bone and joint infection studies. In summary, oral tedizolid appears to be a well-tolerated oral option for Gram-positive bone and joint infections.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Miller,

Flores,

Launer

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Two case reports describe successful tedizolid use for NTM infection in patients with previous linezolid-induced cytopenia [ 72 , 73 ]. Tedizolid has greater antibacterial potency, better pharmacokinetic/pharmacodynamic profiles, and lower hematologic and neurologic toxicity than does linezolid [ 74 , 75 ]. The relatively weak monoamine oxidase inhibition and poor central nervous system penetration of tedizolid may also lead to fewer drug interactions with serotonergic agents [ 76 , 77 ].…”

Section: Emerging Treatmentsmentioning

confidence: 99%

Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) are a group of atypical bacteria that may cause a spectrum of clinical manifestations, including pulmonary, musculoskeletal, skin and soft tissue, and cardiac infections. Antimycobacterial medication regimens for NTM infections require multiple agents with prolonged treatment courses and are often associated with poor tolerance in patients and suboptimal clinical outcomes. This review summarizes NTM pharmacotherapy, including treatment concepts, preferred medication regimens according to NTM species and site of infection, and emerging treatment methods for difficult-totreat species.

show abstract

Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation

Wei,

Zhao,

et al. 2025

Journal of Global Antimicrobial Resistance

View full text Add to dashboard Cite

Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Cited by 10 publications

References 21 publications

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review

Pharmacokinetic/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation

Contact Info

Product

Resources

About